{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:12Z","timestamp":1753891992242,"version":"3.41.2"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Induction chemotherapy followed by concurrent chemoradiotherapy (IC-CCRT) may be beneficial for nasopharyngeal carcinoma. However, the evidence on medium- and long-term effects of IC-CCRT is limited, and new randomized controlled trials (RCTs) have been published after 2018. Therefore, this systematic review and meta-analysis compared survival rates between patients with nasopharyngeal carcinoma receiving IC-CCRT or concurrent chemoradiotherapy (CCRT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Four databases were searched for RCTs on this topic. Two authors independently selected studies, assessed evidence, and extracted data on progression-free survival, overall survival, metastasis-free survival, and local recurrence-free survival. Available data were pooled in a random-effects model and mainly presented in hazard ratio (HR). Heterogeneity and small study effects were also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven RCTs (n = 3345) were deemed eligible. Pooled results revealed that patients receiving IC-CCRT had significantly improved progression-free survival (HR = 0.66, <jats:italic>P<\/jats:italic> &amp;lt; 0.05), overall survival (HR = 0.64, <jats:italic>P<\/jats:italic> &amp;lt; 0.05), metastasis-free survival (HR = 0.58, <jats:italic>P<\/jats:italic> &amp;lt; 0.05), and local recurrence-free survival (HR = 0.69, <jats:italic>P<\/jats:italic> &amp;lt; 0.05) at 3 years, but no significant difference in 5-year overall survival was noted between IC-CCRT and CCRT (HR = 0.84, <jats:italic>P<\/jats:italic> &amp;gt; 0.05). Most findings had low heterogeneity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IC-CCRT may benefit patients with nasopharyngeal carcinoma in the medium term, although no significant difference was observed in 5-year survival compared with CCRT. All outcomes had decreased survival rate from the 3-years to 5-year follow-up. Differences in patient ethnicities and regimens of IC-CCRT may be sources of heterogeneity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.965719","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T10:45:33Z","timestamp":1663065933000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of induction chemotherapy with concurrent chemoradiotherapy on nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Ting-Chieh","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Fang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-No","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"volume-title":"Nasopharyngeal carcinoma","year":"1999","author":"Gibb","key":"B1"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer group 1990 to 2015: A systematic analysis for the global burden of disease study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer group 1990 to 2016: A systematic analysis for the global burden of disease study","volume":"4","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0353","article-title":"The enigmatic epidemiology of nasopharyngeal carcinoma","volume":"15","author":"Chang","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-6-32","article-title":"Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of southern China","volume":"6","author":"Fang","year":"2008","journal-title":"J Trans Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.11.012","article-title":"New data tells us more about cancer incidence in north Africa","volume":"46","author":"Zanetti","year":"2010","journal-title":"Eur J Cancer"},{"volume-title":"Cancer incidence in five continents","year":"2013","author":"Forman","key":"B7"},{"volume-title":"Nasopharyngeal carcinoma","year":"2018","author":"Tsang","key":"B8"},{"key":"B9","unstructured":"Cancer of the nasopharynx2018"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2015.05.006","article-title":"Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma\u2013a time-to-event meta-analysis","volume":"51","author":"Song","year":"2015","journal-title":"Oral Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10237","article-title":"Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.02.027","article-title":"Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis","volume":"129","author":"Tan","year":"2018","journal-title":"Radiother Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0522","article-title":"A pairwise meta-analysis of induction chemotherapy in nasopharyngeal carcinoma","volume":"24","author":"Ouyang","year":"2019","journal-title":"Oncologist"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-020-06218-x","article-title":"The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis","volume":"278","author":"Tang","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12885-020-06912-3","article-title":"The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019360","article-title":"The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials","volume":"99","author":"Wang","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7150\/jca.11814","article-title":"Efficacy of the additional neoadjuvant chemotherapy to concurrent chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis of randomized controlled trials","volume":"6","author":"Chen","year":"2015","journal-title":"J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S96983","article-title":"The role of induction and adjuvant chemotherapy in combination with concurrent chemoradiotherapy for nasopharyngeal cancer: a Bayesian network meta-analysis of published randomized controlled trials","volume":"9","author":"Yu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","article-title":"What is the best treatment of locally advanced nasopharyngeal carcinoma? an individual patient data network meta-analysis","volume":"35","author":"Ribassin-Majed","year":"2017","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/thno.21815","article-title":"The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from Two\/Three-dimensional radiotherapy to intensity-modulated radiotherapy: A network meta-analysis","volume":"7","author":"You","year":"2017","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00597","article-title":"The changing role of chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A updated systemic review and network meta-analysis","volume":"8","author":"Liu","year":"2018","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.21037\/atm.2019.02.15","article-title":"Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma","volume":"7","author":"He","year":"2019","journal-title":"Ann Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S185932","article-title":"Evolutionary role of chemotherapy in advanced nasopharyngeal carcinoma: a literature-based network meta-analysis","volume":"11","author":"Li","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02142-7","article-title":"The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis","volume":"22","author":"Zhou","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1545","article-title":"Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma","volume":"27","author":"Hui","year":"2009","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr116","article-title":"Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic cooperative oncology group (HeCOG) with biomarker evaluation","volume":"23","author":"Fountzilas","year":"2012","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-8179.2012.11.009","article-title":"Efficacy of induction chemotherapy combined with concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma","volume":"39","author":"Huang","year":"2012","journal-title":"Chin Oncol Clinics"},{"key":"B28","article-title":"A prospective and randomized study of induction chemotherapy combined with concurrent chemoradiotherapy in the treatment for nasopharyngeal carcinoma stage T 3\u223c4 n 2\u223c3 M0","volume":"19","author":"Gao","year":"2013","journal-title":"J Chin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.01.002","article-title":"Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2\/3 trial in locally advanced nasopharyngeal carcinoma","volume":"91","author":"Tan","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40880-016-0157-4","article-title":"Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma","volume":"35","author":"Li","year":"2016","journal-title":"Chin J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","article-title":"Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial","volume":"75","author":"Cao","year":"2017","journal-title":"Eur J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2017.03.007","article-title":"The effect of adding neoadjuvant chemotherapy to concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA","volume":"10","author":"Jin","year":"2017","journal-title":"Transl Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.13619","article-title":"Association of chemoradiotherapy regimens and survival among patients with nasopharyngeal carcinoma: A systematic review and meta-analysis","volume":"2","author":"Zhang","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx770","article-title":"A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)","volume":"29","author":"Frikha","year":"2018","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy249","article-title":"Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan cooperative oncology group (TCOG) 1303 study","volume":"29","author":"Hong","year":"2018","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial","volume":"145","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial","volume":"119","author":"Yang","year":"2019","journal-title":"Eur J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Bmj"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"B42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.radonc.2017.12.002","article-title":"Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial","volume":"129","author":"Zhang","year":"2018","journal-title":"Radiother Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40880-019-0385-5","article-title":"Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma","volume":"39","author":"Zhang","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3857\/roj.2019.00311","article-title":"Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management","volume":"37","author":"Ahn","year":"2019","journal-title":"Radiat Oncol J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2656","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: Individual patient data pooled analysis of four randomized trials","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"105494","DOI":"10.1016\/j.oraloncology.2021.105494","article-title":"The impact of induction chemotherapy on long-term quality of life in patients with locoregionally advanced nasopharyngeal carcinoma: Outcomes from a randomised phase 3 trial","volume":"121","author":"Yang","year":"2021","journal-title":"Oral Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.868070","article-title":"5-fluorouracil combined with cisplatin via arterial induction for advanced T-stage nasopharyngeal carcinoma: A 10-year outcome of a phase I\/II study","volume":"12","author":"Xiang","year":"2022","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13022","article-title":"Quality-adjusted life years and disability-adjusted life years are better with concurrent chemoradiation therapy than induction chemotherapy followed by chemoradiation therapy in nasopharyngeal carcinoma","volume":"13","author":"Nittala","year":"2021","journal-title":"Cureus"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.965719\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T10:45:53Z","timestamp":1663065953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.965719\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":48,"alternative-id":["10.3389\/fonc.2022.965719"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.965719","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"article-number":"965719"}}